Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 274

1.

Adult respiratory distress syndrome after treatment with pegylated interferon alpha-2a and ribavirin.

Vartany E, Caldwell CA, Trow TK.

Heart Lung. 2008 Mar-Apr;37(2):153-6. doi: 10.1016/j.hrtlng.2007.10.002. Review.

PMID:
18371508
2.

Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C.

Condat B, Asselah T, Zanditenas D, Estampes B, Cohen A, O'Toole D, Bonnet J, Ngo Y, Marcellin P, Blazquez M.

Eur J Gastroenterol Hepatol. 2006 Mar;18(3):287-9. Review.

PMID:
16462543
3.

Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.

Antonini MG, Babudieri S, Maida I, Baiguera C, Zanini B, Fenu L, Dettori G, Manno D, Mura MS, Carosi G, Puoti M.

Infection. 2008 Jun;36(3):250-5. doi: 10.1007/s15010-007-7132-6. Epub 2008 May 3.

PMID:
18458815
4.
5.

[Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].

Halász T, Farkas A, Tolvaj G, Horváth G.

Orv Hetil. 2006 Feb 19;147(7):321-4. Hungarian.

PMID:
17489160
6.

Reversible myopathy during successful treatment with pegylated interferon and ribavirin for acute hepatitis C.

Golstein PE, Delforge ML, Deviere J, Marcellin P.

J Viral Hepat. 2004 Mar;11(2):183-6.

PMID:
14996354
7.

Tubo-ovarian abscess during therapy of chronic hepatitis C with pegylated interferon and ribavirin.

Inglot M, Szymczak A, Fleischer-Stepniewska K, Fleischer M, Staszek-Zurowska B, Gladysz A.

Neuro Endocrinol Lett. 2011;32(1):1-3.

PMID:
21407153
8.

Major depressive episode with psychotic features induced by pegylated interferon-alpha-2b and ribavirin treatment.

Sockalingam S, Balderson K.

Int Clin Psychopharmacol. 2005 Sep;20(5):289-90.

PMID:
16096520
9.
10.
11.

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.

Carriero D, Fabrizi F, Uriel AJ, Park J, Martin P, Dieterich DT.

Int J Artif Organs. 2008 Apr;31(4):295-302.

PMID:
18432584
12.
13.

[Pulmonary toxicity by pegylated interferon alpha-2a in a patient with chronic hepatitis C].

Son BK, Sohn JH, Kim TY, Park YK, Jeon YC, Han DS.

Korean J Hepatol. 2007 Mar;13(1):103-7. Korean.

14.

[Hepatitis C therapy is not pleasant. Patients must be prepared!].

[No authors listed]

MMW Fortschr Med. 2003 Jan 23;145(3-4):57. German. No abstract available.

PMID:
12619237
15.

Incidence of psychiatric side effects during pegylated interferon- alpha retreatment in nonresponder hepatitis C virus-infected patients.

Quarantini LC, Bressan RA, Galvão A, Batista-Neves S, Paraná R, Miranda-Scippa A.

Liver Int. 2007 Oct;27(8):1098-102.

PMID:
17845538
16.

Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin.

Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, Lindh G, Enquist R, Quist A.

J Viral Hepat. 2008 Sep;15(9):641-5. doi: 10.1111/j.1365-2893.2008.00999.x. Epub 2008 May 27.

PMID:
18507753
17.

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.

El Makhzangy H, Esmat G, Said M, Elraziky M, Shouman S, Refai R, Rekacewicz C, Gad RR, Vignier N, Abdel-Hamid M, Zalata K, Bedossa P, Pol S, Fontanet A, Mohamed MK.

J Med Virol. 2009 Sep;81(9):1576-83. doi: 10.1002/jmv.21570.

PMID:
19626613
18.

Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.

Lawitz E, Rodriguez-Torres M, Muir AJ, Kieffer TL, McNair L, Khunvichai A, McHutchison JG.

J Hepatol. 2008 Aug;49(2):163-9. doi: 10.1016/j.jhep.2008.03.027. Epub 2008 Apr 29.

PMID:
18486984
19.

[Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].

[No authors listed]

MMW Fortschr Med. 2002 Sep 19;144(38):59. German. No abstract available.

PMID:
12395712
20.

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response.

Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, Stauber R, Bischof M, Bauer B, Datz C, Löschenberger K, Formann E, Staufer K, Steindl-Munda P; Austrian Hepatitis Study Group.

Gastroenterology. 2008 Aug;135(2):451-8. doi: 10.1053/j.gastro.2008.04.015. Epub 2008 May 27.

PMID:
18503773
Items per page

Supplemental Content

Write to the Help Desk